Assessment of different biomarkers provides valuable diagnostic standards in the evaluation of the risk of acute rejection

作者：Zheng Jin; Ding Xiaoming; Tian Xiaohui; Jin Zhankui; Pan Xiaoming; Yan Hang; Feng Xinshun; Hou Jun; Xiang Heli; Ren Li; Tian Puxun; Xue Wujun^*

来源：Acta Biochimica et Biophysica Sinica, 2012, 44(9): 730-736.

DOI：10.1093/abbs/gms056

• renal transplant
• acute rejection
• HLA-G5
• sCD30
• iATP

Acute rejection (AR) is a strong risk factor for chronic rejection in renal transplant recipients. Accurate and timely diagnosis of AR episodes is very important for disease control and prognosis. Therefore, objectively evaluated the immune status of patients is essential in the field of post-transplantation treatment. This longitudinal study investigated the usefulness of five biomarkers, human leukocyte antigen (HLA)-G5 and sCD30 level in sera, intracellular adenosine triphosphate (iATP) release level of CD4 T cells, and granzyme B/perforin expression in peripheral blood mononuclear cells (PBMCs) and biopsies, to detect AR and the resolution of biomarkers in a total of 84 cases of renal transplantation. The data demonstrated that recipients with clinical or biopsy proven rejection significantly increased iATP release level of CD4 T cells, and elevated sCD30 but lowered HLA-G5 level in sera compared with individuals with stable graft function. Expression levels of granzyme B and perforin were also elevated in PBMCs and graft biopsies of AR patients. Taken together, we identified that upregulation of sCD30, iATP, granzyme B, perforin, and downregulation of HLA-G5 could provide valuable diagnostic standards to identify those recipients in the risk of AR. And iATP may be a better biomarker than others for predicting the graft rejection episode.

• 出版日期2012-9
• 单位西安交通大学